-
Product Insights
NewLikelihood of Approval Analysis for Chemotherapy Induced Nausea and Vomiting
Overview How likely is it that the drugs in Chemotherapy Induced Nausea and Vomiting will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Chemotherapy Induced Nausea and Vomiting Overview Chemotherapy-induced nausea and...
-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Report Overview Friedreich's Ataxia (FRDA) is a rare, genetic disorder. It is progressive and typically manifests between the ages of 10 and 15. The disorder is characterized by a gradual decline in coordination, muscle strength, and endurance. Individuals with FRDA often become reliant on wheelchairs as the condition advances. The Friedreich Ataxia (FRDA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vonoprazan Fumarate in Reflux Esophagitis (Gastroesophageal Reflux Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vonoprazan Fumarate in Reflux Esophagitis (Gastroesophageal Reflux Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vonoprazan Fumarate in Reflux Esophagitis (Gastroesophageal Reflux...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vonoprazan Fumarate in Nonerosive Reflux Disease (NERD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vonoprazan Fumarate in Nonerosive Reflux Disease (NERD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vonoprazan Fumarate in Nonerosive Reflux Disease (NERD) Drug...
-
Sector Analysis
NewFuchs Endothelial Corneal Dystrophy (FECD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in FECD therapeutics. - More than 133,000,000 total prevalent cases of FECD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FECD. - Currently there are no FDA approved therapies for FECD. The most recent guideline for FECD was developed by the American Academy of Ophthalmology. - The pipeline for FECD mainly consists of enzyme inhibitors Rho kinase 2 inhibitor and mTOR...
-
Sector Analysis
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Report Overview Female sexual dysfunction (FSD) is an umbrella term that encompasses disorders of sexual desire, orgasm, arousal, and sexual pain that result in significant personal distress. FSD is a multifactorial, progressive problem that can occur at any stage of life. It is a complex neurovascular phenomenon that is under the control of psychological, neurovascular, and hormonal factors. Key Mechanisms of Action (Marketed) ·       Receptor Agonist ·       Enzyme Inhibitor ·       Receptor Antagonist...
-
Sector Analysis
NewPeripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in PAD therapeutics. - More than 18,000,000 diagnosed prevalent cases of PAD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for PAD. - The innovator marketed drugs space for PAD includes coagulation factor X inhibitors, fibrinogen activators, hepatocyte growth factor activators, and vascular endothelial growth factor activators, amongst others. - The PAD pipeline mainly includes receptor agonists, followed by biological factor activators...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mycophenolate Mofetil in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mycophenolate Mofetil in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mycophenolate Mofetil in Lupus Nephritis Drug Details: Mycophenolate Mofetil (Cellcept) is...
-
Product Insights
NewLikelihood of Approval Analysis for Type 1 Diabetes (Juvenile Diabetes)
Overview How likely is it that the drugs in Type 1 Diabetes (Juvenile Diabetes) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Type 1 Diabetes (Juvenile Diabetes) Overview Type 1 diabetes,...
-
Sector Analysis
NewPost-Operative Pain (POP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Post-Operative Pain (POP) Marketed and Pipeline Drugs Report Overview Post-operative pain (POP) is considered a form of acute pain due to surgical trauma with an inflammatory reaction and initiation of an afferent neuronal barrage. There could also be some generalized body pain before the operation with aggravation after the operation. This type of operation often needs complete or partial anesthesia. Disturbances in the channels and collaterals or the internal organs may be the cause. Key Mechanisms of Action (Marketed) ·      ...